Vitamin K2 for Bone Health Support

Vitamin K2 is often sold as the nutrient that directs calcium into bone rather than arteries. The biochemistry behind that claim is genuine; the clinical evidence for bone outcomes is narrower than the marketing suggests.

Vitamin K is the cofactor for gamma-carboxylation of osteocalcin, the protein osteoblasts use to bind calcium into bone matrix. Undercarboxylated osteocalcin is common on typical Western intakes and falls reliably with K2 supplementation, so the biomarker case is strong and reproducible. Whether that translates into fewer fractures is contested. High-dose MK-4 at 45 mg daily reduced fractures in Japanese trials, but the large Dutch and Western trials of lower-dose MK-7 have generally shown preserved bone mineral density without clear fracture reduction. K2 also does not increase calcium absorption, despite frequent claims to that effect - that is vitamin D's role.

Bone is continuously remodelled by osteoclasts resorbing mineralised matrix and osteoblasts laying down new collagen that is then mineralised. Calcium absorption from the gut is governed by vitamin D; where calcium is deposited depends on the vitamin K-dependent proteins that handle it.

Vitamin K acts as cofactor for gamma-glutamyl carboxylase, which carboxylates osteocalcin in bone and matrix Gla protein in vascular tissue. Carboxylated osteocalcin binds calcium and hydroxyapatite within the bone matrix, while carboxylated matrix Gla protein inhibits calcification of arterial walls - the mechanistic basis for the calcium-directing narrative. Menaquinone-7 has a longer half-life and better extrahepatic distribution than MK-4 or phylloquinone, which is why it is the common supplemental form, though the strongest fracture data came from high-dose MK-4.

MK-7 at low doses is the practical choice; MK-4 fracture trials used pharmacological doses.

There are currently no studies linked to this pairing in our library, so no study list is shown.

The biochemistry is settled: vitamin K is required for osteocalcin carboxylation, and supplementation reliably reduces undercarboxylated osteocalcin. A three-year trial of 180 mcg MK-7 daily in postmenopausal women showed reduced age-related decline in bone mineral density and vertebral height, and Japanese MK-4 trials at 45 mg reported fracture reduction. Counterweights are significant. Western trials at nutritional MK-7 doses have not demonstrated fracture reduction, the MK-4 results have not replicated outside Japan and used doses far above dietary intake, effects on bone mineral density are small, and most participants were not deficient. K2 does not increase calcium absorption. Osteoporosis treatment evidence for bisphosphonates and denosumab is far stronger.

Vitamin K2 is well tolerated, with no established toxicity threshold and no hypercoagulable effect at supplemental doses in people not taking anticoagulants. Side effects in trials were comparable to placebo.

Established osteoporosis, a fragility fracture, height loss or a T-score below -2.5 warrants medical assessment and consideration of proven pharmacotherapy rather than supplementation alone. Direct oral anticoagulants such as apixaban and rivaroxaban are not affected by vitamin K, but check before combining any supplement with anticoagulation.

Anticoagulation is the decisive issue; the rest are complementary nutrients.

No studies are currently linked to this pairing, so no reference list is available. This section will populate as evidence is added to the library.